Work Here?
About Tango Therapeutics
Industries
Biotechnology
Healthcare
Company Size
51-200
Company Stage
IPO
Headquarters
Boston, Massachusetts
Founded
2017
Overview
Tango Therapeutics develops cancer medicines by leveraging synthetic lethality to selectively kill cancer cells while sparing healthy cells. Its approach focuses on creating drugs that exploit interactions between gene pairs, aiming for targeted therapies that spare normal tissue. The company advances its treatments through a strong R&D program and collaborates with larger pharmaceutical partners, such as Gilead Sciences, to co-develop therapies and accelerate commercialization. Revenue comes from these partnerships and funding rounds like its Series B. Tango differentiates itself with a dedicated emphasis on genetically targeted cancer therapies, a robust pipeline, and leadership that guides strategic collaborations. The company’s goal is to bring next-generation, genetically targeted immunotherapies to market, improving outcomes for cancer patients by precisely targeting tumor biology.
Simplify's Take
What believers are saying
- Pivotal vopimetostat trial initiating 2026 in second-line pancreatic cancer for regulatory approval[3]
- $225 million financing completed October 2025 funds late-stage development and clinical trials[3]
- Positive Phase 1/2 monotherapy data October 2025 demonstrates durable activity across cancer types[3]
What critics are saying
- TNG348 liver toxicity discontinuation signals inability to predict safety liabilities early[2]
- Vopimetostat 43% ORR in cholangiocarcinoma may require full Phase 3, extending cash burn[1]
- Valuation at 41.3x price-to-sales versus industry norms; clinical setback triggers 40-60% correction[1]
What makes Tango Therapeutics unique
- PRMT5 inhibitor vopimetostat targets MTAP-deleted cancers with synthetic lethality approach[3]
- Brain-penetrant TNG456 addresses glioblastoma and solid tumors with 15-fold selective killing[3]
- Combination strategy with Revolution Medicines' RAS inhibitors targets first-line pancreatic cancer[3]
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$743M
Above
Industry Average
Funded Over
6 Rounds
Benefits
Hybrid Work Options
Stock Price
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↑ 4%Adam Crystal, President of R&D at Tango Therapeutics, sold 20,251 shares of common stock on 5 March 2026 for $304,000, according to an SEC Form 4 filing. The sale represented 15.24% of Crystal's direct ownership at the time. The transaction falls within Crystal's Rule 10b5-1 plan and aligns with his historical pattern of periodic sales since February 2025, though the sale size was above his recent median of 19,352 shares. No stock options were exercised in the transaction. Tango Therapeutics is a clinical-stage biotechnology company developing targeted oncology therapies. Its lead candidate, vopimetostat, targets cancers with specific genetic deletions. The company reported $62.38 million in trailing twelve-month revenue and a net loss of $101.59 million.
Tango Therapeutics shares surged 36.28% to $16.83, reaching an all-time high of $16.97 during intraday trading, following a bullish note from Stifel. The investment firm reaffirmed its "buy" rating and $15 price target, 21% above the previous day's close. The biotech company narrowed its 2024 net loss by 22% to $101.59 million, whilst total revenues jumped 48.3% to $62.38 million year-on-year. However, fourth-quarter net loss widened 26% to $38.7 million, with no revenues during the period. Tango Therapeutics plans to initiate clinical trials this year testing drug candidate vopimetostat in combination with multiple inhibitors for pancreatic cancer treatment. The company recently signed a collaboration agreement with Erasca to study vopimetostat combined with ERAS-0015.
Tango Therapeutics to participate in the Guggenheim Emerging Outlook: Biotech Summit 2026. Tango Therapeutics, Inc. +0.48% Pre BOSTON, Feb. 03, 2026 (GLOBE NEWSWIRE) - Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that Malte Peters, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Thursday, February 12, 2026 at 2:00 PM EST. The live webcast will be available under the "Events & Presentations" tab on the "Investors" page of the Company's website on the day of the event. A replay of the webcast will be archived on the Company's website for 90 days following the presentation. About Tango Therapeutics Tango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. For more information, please visit www.tangotx.com. Investors and Media: Elizabeth Hickin [email protected] [email protected] This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.
Top 10 Oncology capital raises and investors in the U.S. - october 16th - november 15th, 2025. Several interesting transactions closed in the Oncology sector over the past two weeks. If you would like more info on these deals or would like to discuss the capital raising market for your company, please contact me. * * Neuphoria Therapeutics, that develops therapies that addresses the complex needs of individuals affected by neuropsychiatric disorders, received $3.28 million of development capital from Lynx1 Capital Management through a private placement. * Tango Therapeutics, biotechnology company that discovers novel drug targets and delivers the next generation of precision medicine for the treatment of cancer, received $197.06 million of development capital from Nextech Invest, Boxer Capital, The Invus Group, TCG Crossover Management, Farallon Capital Management, Logos Capital, Woodline Partners, Balyasny Asset Management, Adage Capital Management and Nantahala Capital Management through a private placement.
Tango Therapeutics (TNGX) announced promising Phase 1/2 data for vopimetostat in MTAP-deleted cancers and raised $210 million to advance its pipeline. Despite a 139% year-to-date share price increase, shares trade at a 30% discount to analyst targets. The current price-to-sales ratio of 41.3x is considered overvalued compared to industry norms. While recent achievements boost confidence, unprofitability and reliance on future breakthroughs pose risks.
Tango Therapeutics is Hiring for 21 Jobs on Simplify!
Find jobs on Simplify and start your career today
About Tango Therapeutics
Industries
Biotechnology
Healthcare
Company Size
51-200
Company Stage
IPO
Headquarters
Boston, Massachusetts
Founded
2017
Tango Therapeutics is Hiring for 21 Jobs on Simplify!
Find jobs on Simplify and start your career today